m-AMSA and adenocarcinoma of the endometrium - A Southwest Oncology Group Study

Robert D. Hilgers, Sewa S. Legha, George A. Johnston, David S Alberts, Ronald L. Stephens, Bill L. Tranum, Edward V. Hannigan

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Twenty-eight patients with advanced or recurrent adenocarcinoma of the endometrium were treated with m-AMSA. Twenty-four patients (86%) were treated at 30 mg/M2/d × 3d q 21 d and four patients were treated at 40 mg/M2/d × 3d q 21 d intravenously. Eighty-eight courses of m-AMSA were administered with a median of 2 courses per patient. One (5%) complete response occurred in 19 patients evaluable for response. Toxicity was well tolerated and generally mild. m-AMSA may be relatively inactive in the treatment of advanced adenocarcinoma of the endometrium; further studies, however, are required to determine its effectiveness in primary previously untreated disease.

Original languageEnglish (US)
Pages (from-to)335-338
Number of pages4
JournalInvestigational New Drugs
Volume2
Issue number3
DOIs
StatePublished - Sep 1984

Fingerprint

Amsacrine
Endometrium
Adenocarcinoma

Keywords

  • 4′-(9-acridinyl-amino)methanesulfon-m-anisidide
  • adenocarcinoma of the endometrium
  • m-AMSA
  • Phase II clinical trial

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Hilgers, R. D., Legha, S. S., Johnston, G. A., Alberts, D. S., Stephens, R. L., Tranum, B. L., & Hannigan, E. V. (1984). m-AMSA and adenocarcinoma of the endometrium - A Southwest Oncology Group Study. Investigational New Drugs, 2(3), 335-338. https://doi.org/10.1007/BF00175388

m-AMSA and adenocarcinoma of the endometrium - A Southwest Oncology Group Study. / Hilgers, Robert D.; Legha, Sewa S.; Johnston, George A.; Alberts, David S; Stephens, Ronald L.; Tranum, Bill L.; Hannigan, Edward V.

In: Investigational New Drugs, Vol. 2, No. 3, 09.1984, p. 335-338.

Research output: Contribution to journalArticle

Hilgers, RD, Legha, SS, Johnston, GA, Alberts, DS, Stephens, RL, Tranum, BL & Hannigan, EV 1984, 'm-AMSA and adenocarcinoma of the endometrium - A Southwest Oncology Group Study', Investigational New Drugs, vol. 2, no. 3, pp. 335-338. https://doi.org/10.1007/BF00175388
Hilgers, Robert D. ; Legha, Sewa S. ; Johnston, George A. ; Alberts, David S ; Stephens, Ronald L. ; Tranum, Bill L. ; Hannigan, Edward V. / m-AMSA and adenocarcinoma of the endometrium - A Southwest Oncology Group Study. In: Investigational New Drugs. 1984 ; Vol. 2, No. 3. pp. 335-338.
@article{96215f9f272c4cc58d72e6f8c848d8b4,
title = "m-AMSA and adenocarcinoma of the endometrium - A Southwest Oncology Group Study",
abstract = "Twenty-eight patients with advanced or recurrent adenocarcinoma of the endometrium were treated with m-AMSA. Twenty-four patients (86{\%}) were treated at 30 mg/M2/d × 3d q 21 d and four patients were treated at 40 mg/M2/d × 3d q 21 d intravenously. Eighty-eight courses of m-AMSA were administered with a median of 2 courses per patient. One (5{\%}) complete response occurred in 19 patients evaluable for response. Toxicity was well tolerated and generally mild. m-AMSA may be relatively inactive in the treatment of advanced adenocarcinoma of the endometrium; further studies, however, are required to determine its effectiveness in primary previously untreated disease.",
keywords = "4′-(9-acridinyl-amino)methanesulfon-m-anisidide, adenocarcinoma of the endometrium, m-AMSA, Phase II clinical trial",
author = "Hilgers, {Robert D.} and Legha, {Sewa S.} and Johnston, {George A.} and Alberts, {David S} and Stephens, {Ronald L.} and Tranum, {Bill L.} and Hannigan, {Edward V.}",
year = "1984",
month = "9",
doi = "10.1007/BF00175388",
language = "English (US)",
volume = "2",
pages = "335--338",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - m-AMSA and adenocarcinoma of the endometrium - A Southwest Oncology Group Study

AU - Hilgers, Robert D.

AU - Legha, Sewa S.

AU - Johnston, George A.

AU - Alberts, David S

AU - Stephens, Ronald L.

AU - Tranum, Bill L.

AU - Hannigan, Edward V.

PY - 1984/9

Y1 - 1984/9

N2 - Twenty-eight patients with advanced or recurrent adenocarcinoma of the endometrium were treated with m-AMSA. Twenty-four patients (86%) were treated at 30 mg/M2/d × 3d q 21 d and four patients were treated at 40 mg/M2/d × 3d q 21 d intravenously. Eighty-eight courses of m-AMSA were administered with a median of 2 courses per patient. One (5%) complete response occurred in 19 patients evaluable for response. Toxicity was well tolerated and generally mild. m-AMSA may be relatively inactive in the treatment of advanced adenocarcinoma of the endometrium; further studies, however, are required to determine its effectiveness in primary previously untreated disease.

AB - Twenty-eight patients with advanced or recurrent adenocarcinoma of the endometrium were treated with m-AMSA. Twenty-four patients (86%) were treated at 30 mg/M2/d × 3d q 21 d and four patients were treated at 40 mg/M2/d × 3d q 21 d intravenously. Eighty-eight courses of m-AMSA were administered with a median of 2 courses per patient. One (5%) complete response occurred in 19 patients evaluable for response. Toxicity was well tolerated and generally mild. m-AMSA may be relatively inactive in the treatment of advanced adenocarcinoma of the endometrium; further studies, however, are required to determine its effectiveness in primary previously untreated disease.

KW - 4′-(9-acridinyl-amino)methanesulfon-m-anisidide

KW - adenocarcinoma of the endometrium

KW - m-AMSA

KW - Phase II clinical trial

UR - http://www.scopus.com/inward/record.url?scp=0021229501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021229501&partnerID=8YFLogxK

U2 - 10.1007/BF00175388

DO - 10.1007/BF00175388

M3 - Article

C2 - 6548984

AN - SCOPUS:0021229501

VL - 2

SP - 335

EP - 338

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -